March 2, 2017
This session will discuss how inhaled therapies are used to treat some patients with pulmonary arterial hypertension (PAH). An overview of the two FDA-approved inhaled prostacyclins are provided, along with discussion of appropriate patient selection and management of side effects.
John Wesley McConnell, MD, Kentuckiana Pulmonary Associates
Eric Fenstad, MD, IHA Pulmonary, Critical Care and Sleep Consultants
Nimaljeet Tarango, RN, MS, NP, UCSF Medical Center
Debra Zupancic, FNP, BC, University of Colorado, Denver